Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted ...

The Jamaican-Canadian supermodel reflects on confidence, beauty standards, and raising awareness without letting vitiligo ...

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte Corporation has recently completed a clinical study titled An ...

Mr. Hoppenot joined Incyte in 2014 and previously served as Chairman and CEO. "On behalf of the Board of Directors, I would ...

If you are wondering whether Incyte at around $96.70 is still a smart buy after its big run, you are in the right place to dig into what the market might be getting right or wrong about its value.

Incyte ( ($INCY) ) has provided an announcement. On December 10, 2025, Hervé Hoppenot announced his retirement from Incyte Corporation’s Board of ...

Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte today and set a price target of $84.00. According to TipRanks, Abrahams is a 4-star analyst with an average return of 6.6% and a ...

Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential ...

Based on Incyte’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.37 billion and a net profit of $424.17 million. In comparison, last year ...

The supermodel opens up about connecting with her inner child and creating the resources she never had growing up.

Shares are up 7% in trading today, after Geron announced a strategic restructuring to "position the company for long-term ...